Shots:

• Boehringer Ingelheim has accepted a GalXC RNAi candidate (DCR-LIV2) for advancement under the existing agreement b/w the companies for the discovery and development of novel therapies for chronic liver diseases
• Dicerna will receive $170M as development and commercial milestones related to DCR-LIV2 and is eligible to receive royalties on net sales of the therapy
• Boehringer Ingelheim will evaluate DCR-LIV2 for the treatment of NASH

 Ref: Dicerna | Image: New England Real Estate Journal